Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7843630 | 0.76 | ELANE (0.39) | ELANE | |
| SCHEMBL28694365 | 0.72 | CHRNB2 (0.36) | CHRNB2CHRNA4MCHR1 | |
| SCHEMBL29499452 | 0.72 | SLC7A5 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL1472705 | 0.72 | SLC7A5 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL24617877 | 0.72 | CHRNB2 (0.36) | CHRNB2CHRNA4MCHR1 | |
| SCHEMBL15918726 | 0.70 | CHRNB2 (0.42) | CHRNB2CHRNA4MCHR1 | |
| SCHEMBL9196159 | 0.70 | ACHE (0.41) | ELANE | |
| SCHEMBL2008822 | 0.70 | ELANE (0.56) | ELANE | |
| SCHEMBL10329129 | 0.69 | CHRNB2 (0.35) | CHRNB2CHRNA4 | |
| SCHEMBL29790285 | 0.69 | CA12 (0.41) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078132-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | ONCOSPHERIX INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4587442-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | ONCOSPHERIX INC. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024059491-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | ONCOSPHERIX INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011133659-A2 | INHIBITORS OF HIF AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | HIF1AN, HIF1A, EGLN2 | CHRNB2 4741/4885CHRNA4 4804/4885ELANE 2700/4885 |
| US-20260078132-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | VHL, HIF1AN, HIF1A | CHRNB2 4157/4885CHRNA4 4713/4885ELANE 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.